A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

BACKGROUND: Sapanisertib is an oral, highly selective inhibitor of mammalian target of rapamycin complexes 1 and 2. OBJECTIVE: The aim of this study was to assess the safety, tolerability, pharmacokinetics, preliminary efficacy, and to establish the recommended phase 2 dose (RP2D) of sapanisertib. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Kuboki, Yasutoshi, Lin, Chia-Chi, Yonemori, Kan, Yanai, Tomoko, Faller, Douglas V., Dobler, lwona, Gupta, Neeraj, Sedarati, Farhad, Kim, Kyu-pyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994735/
https://www.ncbi.nlm.nih.gov/pubmed/34843044
http://dx.doi.org/10.1007/s11523-021-00855-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994735/
https://www.ncbi.nlm.nih.gov/pubmed/34843044
http://dx.doi.org/10.1007/s11523-021-00855-w

Ejemplares similares